GlassScriptPhysician profile
Vahid Tohidi
NPI 1356766786
$2,985.83
in general payments reported to CMS, 2019-2025
30 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.43 · 2022: $524 · 2023: $598 · 2024: $909 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.86 |
| Education | $112.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.20 | 2021-2025 | Duopa, Qulipta, Botox |
| Biogen, INC. | $300.96 | 2022-2025 | Spinraza, Qalsody, Skyclarys |
| Edw Pharma, INC. | $268.48 | 2024 | Tiglutik |
| Alexion Pharmaceuticals, INC. | $206.20 | 2022-2025 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $202.75 | 2022-2025 | Firdapse |
| Argenx US, INC. | $163.49 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $156.92 | 2022-2024 | Evrysdi |
| Acadia Pharmaceuticals INC | $138.79 | 2022-2025 | Nuplazid, Daybue |
| Tanabe Pharma America, INC. | $135.76 | 2021-2025 | Radicava |
| Amgen INC. | $123.06 | 2024-2025 | Uplizna |
| Itf Therapeutics LLC | $112.80 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $81.40 | 2023-2024 | Nuedexta |
| Alnylam Pharmaceuticals INC. | $78.04 | 2022-2023 | Onpattro |
| Grifols USA, LLC | $72.60 | 2023-2025 | Gamunex-C |
| Lilly USA, LLC | $62.40 | 2022-2024 | Emgality, Reyvow |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.39 | 2024-2025 | Hyqvia |
| Genzyme Corporation | $48.00 | 2025 | |
| Csl Behring | $47.65 | 2025 | Hizentra |
| Ucb, INC. | $45.28 | 2022 | |
| Grt US Holding, INC. | $23.81 | 2022 | |
| Insightec,INC | $21.29 | 2023 | Exablate |
| Allergan, INC. | $21.09 | 2022 | |
| Pfizer INC. | $19.56 | 2024 | |
| Emd Serono, INC. | $19.23 | 2022 | |
| Neurocrine Biosciences, INC. | $19.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.77 | 2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Aucta Pharmaceuticals, INC. | $16.68 | 2025 | Motpoly Xr |
| Ani Pharmaceuticals, INC. | $15.20 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahid Tohidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.